Fosun Pharmaceutical (02196.HK): Ketoprofen patches approved for clinical trials.

Zhixin Finance APP News, Fosun Pharma (02196.HK) announced recently that its subsidiary, Shanghai Zhaohui Pharmaceutical Co., Ltd. ("Zhaohui Pharmaceutical"), has received approval from the National Medical Products Administration to conduct clinical trials on ketoprofen patches. Zhaohui Pharmaceutical plans to conduct Phase III clinical trials for this drug in China when the conditions are met. This drug is a chemical drug mainly used for (1) pain relief and anti-inflammatory purposes for diseases and symptoms such as low back pain (muscle fasciitis, degenerative spine changes, intervertebral disc diseases, and lumbar sprains), osteoarthritis, shoulder periarthritis, tendinitis, tenosynovitis, lateral epicondylitis (tennis elbow), muscle pain, and swelling and pain from injuries, and (2) local pain relief for rheumatoid arthritis.